Get insights into the top gainers and losers of Tuesday's after-hours session. After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
SPERO THERAPEUTICS INC (NASDAQ:SPRO) Reports Mixed Q2 2025 Results with Revenue Beat but Stock Decline SPERO Therapeutics (SPRO) reported Q2 2025 results with $14.19M revenue, beating estimates, but shares fell 6.8%. Phase 3 trial for tebipenem HBr halted early for efficacy.
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Unusual volume stocks in Friday's session Discover the stocks with unexpected trading volume in today's session on the US markets.
These stocks are making the most noise in today's session. Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.
